Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations

Journal of Genetics

Volumn 94, Issue 4, 2015, Pages 765-770

  ABDELHEDI, R A N I A ^a   BOUAYED, NOUHA ABDELMOULA ^b   ALFADHLI, S U A D ^c   ABID, L E I L A ^d   REBAI, A H M E D ^a   KHARRAT, N A J L A ^a  

^a CENTRE DE BIOTECHNOLOGIE DE SFAX   (Tunisia)

^b UNIVERSITY OF SFAX   (Tunisia)

^c Department of Medical Laboratory Sciences ^*  (Kuwait)

^d HEDI CHAKER HOSPITAL   (Tunisia)

Author keywords

Bahraini; CYP450; Kuwaiti; linkage disequilibrium; polymorphisms; Tunisian

Indexed keywords

CYP2C19 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9;

ADULT; BAHRAIN; DRUG INACTIVATION; GENETIC POLYMORPHISM; GENETICS; HUMAN; KUWAIT; MIDDLE AGED; TUNISIA;

ADULT; BAHRAIN; CYTOCHROME P-450 CYP2C19; CYTOCHROME P-450 CYP2C9; HUMANS; INACTIVATION, METABOLIC; KUWAIT; MIDDLE AGED; POLYMORPHISM, GENETIC; TUNISIA;

EID: 84953637497     PISSN: 00221333     EISSN: 09737731     Source Type: Journal    
DOI: 10.1007/s12041-015-0581-2     Document Type: Article

References (20)

1. Allabi A. C., Gala J. L., Desager J. P., Heusterspreute M. and Horsmans Y. 2003 Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br. J. Clin. Pharmacol.56, 653–657.
2. Alzahrani A. M., Ragia G., Hanieh H. and Manolopoulos V. G. 2013 Genotyping of CYP2C9 and VKORC1 in the Arabic population of Al-Ahsa, Saudi Arabia. Biomed. Res. Int.2013, 315980.
3. Azarpira N., Namazi S., Hendijani F., Banan M. and Darai M. 2010 Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran. Pharmacol. Rep.62, 740–746.
4. Dandara C., Lombard Z., Du Plooy I., McLellan T., Norris S. A. and Ramsay M. 2011 Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black south African population: a window into diversity. Pharmacogenomics12, 1663–1670.
5. Goldstein J. A., Ishizaki T., Chiba K., de Morais S. M., Bell D., Krahn P. M. et al. 1997 Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics7, 59–64.
6. Gurbel P. A., Tantry U. S., Shuldiner A. R. and Kereiakes D. J. 2010 Genotyping: one piece of the puzzle to personalize antiplatelet therapy. J. Am. Coll. Cardiol.56, 112–116.
7. Hamdy S. I., Hiratsuka M., Narahara K., El-Enany M., Moursi N., Ahmed M. S. et al. 2002 Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br. J. Clin Pharmacol.53, 596–603.
8. Kim K. A., Song W. K., Kim K. R. and Park J. Y. 2010 Assessment of CYP2C19 genetic polymorphisms in a Korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles. J. Clin. Pharm. Ther.35, 697–703.
9. Kurdzi W., Dodoo A. N. and Mills J. J. 2009 Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med. Genet.2, 124.
10. Kurose K., Sugiyama E. and Saito Y. 2012 Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug. Metab. Pharmacokinet.27, 9–54.
11. Marcadet A., O’Connel P. and Cohen D. 1987 Standardized Southern blot workshop techniques. In: Histocompatibility testing (ed. B. Dupont), pp. 587–590. Springer, New York, USA.
12. Ninomiya H., Mamiya K., Matsuo S., Ieiri I., Higuchi S. and Tashiro N. 2000 Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. Ther. Drug Monit.22, 230–232.
13. Pedersen R. S., Brasch-Andersen C., Sim S. C., Bergmann T. K., Halling J., Petersen M. S. et al. 2010 Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur. J. Clin. Pharmacol.66, 1199– 1205.
14. Persson I., Aklillu E., Rodrigues F., Bertilsson L. and Ingelman-Sundberg M. 1996 S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics6, 521–526.
15. Scordo M. G., Caputi A. P., D’Arrigo C., Fava G. and Spina E. 2004 Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol. Res.50, 195–200.
16. Sibbing D., Koch W., Gebhard D., Schuster T., Braun S., Stegherr J. et al. 2010 Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation121, 512–518.
17. Suarez-Kurtz G. 2011 Linkage disequilibrium between the CYP2C19*17 and CYP2C8*2 alleles in populations of African descent. Eur. J. Clin. Pharmacol.67, 211–212.
18. Vicente J., González-Andrade F., Soriano A., Fanlo A., Martínez-Jarreta B. and Sinués B. 2014 Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study. Mol. Biol. Rep.41, 1267–1272.
19. Yang J. Q., Morin S., Verstuyft C., Fan L. A., Zhang Y., Xu C. D. et al. 2003 Frequency of cytochrome P4502C9 allelic variants in the Chinese and French populations. Fundam. Clin. Pharmacol.17, 373–376.
20. Yousef A. M., Bulatova N. R., Newman W., Hakooz N., Ismail S., Qusa H. et al. 2012 Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population. Mol. Biol. Rep.39, 9423–9433.